ERBB2 (V777_G778insCG)
Sign in to save this workspaceERBB2 · Variant type: indel · HGVS: p.V777_G778insCG
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Pralsetinib | 100.0% | 0.0% | 93.43 |
| 2 | Afatinib | 99.9% | 0.1% | 98.50 |
| 3 | Mobocertinib | 99.7% | 0.3% | 97.22 |
| 4 | Osimertinib | 99.5% | 0.5% | 97.24 |
| 5 | Canertinib | 99.3% | 0.7% | 96.49 |
| 6 | Dacomitinib | 99.2% | 0.8% | 97.99 |
| 7 | Lazertinib | 99.1% | 0.9% | 97.47 |
| 8 | Neratinib | 97.7% | 2.3% | 93.18 |
| 9 | Ibrutinib | 96.0% | 4.0% | 94.74 |
| 10 | Gefitinib | 95.6% | 4.4% | 99.25 |
| 11 | Lapatinib | 95.5% | 4.5% | 99.25 |
| 12 | Brigatinib | 94.8% | 5.2% | 82.96 |
| 13 | Bosutinib | 94.7% | 5.3% | 87.22 |
| 14 | Vandetanib | 87.8% | 12.2% | 95.74 |
| 15 | Darovasertib | 83.4% | 16.6% | 96.99 |
| 16 | Avapritinib | 78.8% | 21.2% | 97.73 |
| 17 | Fostamatinib | 77.3% | 22.7% | 96.74 |
| 18 | Erlotinib | 73.1% | 26.9% | 99.75 |
| 19 | Dasatinib | 69.9% | 30.1% | 87.97 |
| 20 | Pacritinib | 67.7% | 32.4% | 88.64 |
| 21 | Alectinib | 67.1% | 32.9% | 95.49 |
| 22 | Alpelisib | 57.0% | 43.0% | 97.22 |
| 23 | Ponatinib | 53.4% | 46.6% | 78.23 |
| 24 | Defactinib | 53.4% | 46.6% | 92.68 |
| 25 | Zanubrutinib | 52.4% | 47.6% | 98.24 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Pralsetinib | 100.0% | — | — |
| Afatinib | 99.9% | — | — |
| Mobocertinib | 99.7% | — | — |
| Osimertinib | 99.5% | — | — |
| Canertinib | 99.3% | — | — |
| Dacomitinib | 99.2% | — | — |
| Lazertinib | 99.1% | — | — |
| Neratinib | 97.7% | — | — |
| Ibrutinib | 96.0% | — | — |
| Gefitinib | 95.6% | — | — |
| Lapatinib | 95.5% | — | — |
| Brigatinib | 94.8% | — | — |
| Bosutinib | 94.7% | — | — |
| Vandetanib | 87.8% | — | — |
| Darovasertib | 83.4% | — | — |
| Avapritinib | 78.8% | — | — |
| Fostamatinib | 77.3% | — | — |
| Erlotinib | 73.1% | — | — |
| Dasatinib | 69.9% | — | — |
| Pacritinib | 67.7% | — | — |
| Alectinib | 67.1% | — | — |
| Alpelisib | 57.0% | — | — |
| Ponatinib | 53.4% | — | — |
| Defactinib | 53.4% | — | — |
| Zanubrutinib | 52.4% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 16.3ms